Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence

Completed · Phase 3 · Has a placebo group

Conditions studied: Overactive Bladder

In brief

The purpose of this study is to assess the safety and effectiveness of botulinum toxin type A (onabotulinumtoxinA) in treating patients with idiopathic overactive bladder with urinary incontinence.

Key facts

Study ID

NCT00910520

Run by

Allergan

People needed

548

Starts

2009-09-01

Expected to finish

2011-08-01

Last updated by the study team

2013-03-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Symptoms of OAB (frequency/urgency) with urinary incontinence for at least 6 months
• Inadequate response or limiting side effects with anticholinergics for the treatment of OAB

You may not qualify if…

• Overactive Bladder caused by neurological condition
• Patient has predominance of stress incontinence
• History or evidence of pelvic or urological abnormality

Where it is running

• Study site — Laguna Hills, California, United States
• Study site — Ghent, Belgium
• Study site — Prague, Czechia
• Study site — Tübingen, Germany
• Study site — Warsaw, Poland
• Study site — Moscow, Russia
• Study site — London, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.